Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.
Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, Parhofer K, Ramlow W, Koch M, Utermann G, Labarrere CA, Seidel D; Group of Clinical Investigators. Jaeger BR, et al. Among authors: ramlow w. Nat Clin Pract Cardiovasc Med. 2009 Mar;6(3):229-39. doi: 10.1038/ncpcardio1456. Nat Clin Pract Cardiovasc Med. 2009. PMID: 19234501 Clinical Trial.
Current view: indications for extracorporeal lipid apheresis treatment.
Schettler V, Neumann CL, Hulpke-Wette M, Hagenah GC, Schulz EG, Wieland E; German Apheresis Working Group. Schettler V, et al. Clin Res Cardiol Suppl. 2012 Jun;7(Suppl 1):15-9. doi: 10.1007/s11789-012-0046-6. Clin Res Cardiol Suppl. 2012. PMID: 22528134 Free PMC article.
First data from the German Lipoprotein Apheresis Registry (GLAR).
Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Ramlow W, Blume H; Scientific Board of GLAR for the German Apheresis Working Group. Schettler VJ, et al. Among authors: ramlow w. Atheroscler Suppl. 2015 May;18:41-4. doi: 10.1016/j.atherosclerosissup.2015.02.006. Atheroscler Suppl. 2015. PMID: 25936303
TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U, Illigens BM, Siepmann T, Arneth B, Siegert G, Siegels D, Heigl F, Hettich R, Ramlow W, Prophet H, Bornstein SR, Julius U. Schatz U, et al. Among authors: ramlow w. Atheroscler Suppl. 2015 May;18:199-208. doi: 10.1016/j.atherosclerosissup.2015.02.030. Atheroscler Suppl. 2015. PMID: 25936327
Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial.
Moriarty PM, Parhofer KG, Babirak SP, deGoma E, Duell PB, Hohenstein B, Ramlow W, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G. Moriarty PM, et al. Among authors: ramlow w. J Clin Lipidol. 2016 May-Jun;10(3):627-34. doi: 10.1016/j.jacl.2016.02.003. Epub 2016 Feb 18. J Clin Lipidol. 2016. PMID: 27206951 Clinical Trial.
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.
Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, Leebmann J, Ramlow W, Schettler V, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G. Moriarty PM, et al. Among authors: ramlow w. Eur Heart J. 2016 Dec 21;37(48):3588-3595. doi: 10.1093/eurheartj/ehw388. Epub 2016 Aug 29. Eur Heart J. 2016. PMID: 27572070 Free PMC article. Clinical Trial.
Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W. Hohenstein B, et al. Among authors: ramlow w. Atheroscler Suppl. 2017 Nov;30:180-186. doi: 10.1016/j.atherosclerosissup.2017.05.009. Epub 2017 Jun 1. Atheroscler Suppl. 2017. PMID: 29096835 Clinical Trial.
Efficacy of lipid reduction with DALI and MONET.
Ramlow W, Röseler E, Heigl F, Spitthöver R, Ringel J, Schmitz G, Heinzler R, Abdul-Rahman N, Leistikow F, Himmelsbach F, Schettler V, Pham J, Kozik-Jaromin J. Ramlow W, et al. Atheroscler Suppl. 2017 Nov;30:217-224. doi: 10.1016/j.atherosclerosissup.2017.05.035. Epub 2017 Jun 1. Atheroscler Suppl. 2017. PMID: 29096841
Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational study.
Kozik-Jaromin J, Röseler E, Heigl F, Spitthöver R, Ringel J, Schmitz G, Heinzler R, Abdul-Rahman N, Leistikow F, Himmelsbach F, Schettler V, Uhlenbusch-Körwer I, Ramlow W. Kozik-Jaromin J, et al. Among authors: ramlow w. Atheroscler Suppl. 2017 Nov;30:225-231. doi: 10.1016/j.atherosclerosissup.2017.05.036. Atheroscler Suppl. 2017. PMID: 29096842
58 results